Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer, extending median overall survival to ...
RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...
NHWD-870 HCl achieves 45% response rate in thoracic NUT carcinoma, nearly doubling the overall cohort's 30% rate in advanced ...
AI can generate 100x more drug candidates, but trials still need real patients. The bottleneck has shifted, and most sponsors ...
FDA AI Guidance requires clinical trial sponsors to validate algorithms before submission, shifting documentation and testing ...
ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase ...
UP Oncolytics secures $2.5M NIH funding to advance engineered Zika virus glioblastoma therapy toward first human trial, ...
Lilly's sofetabart mipitecan achieves 79% response rate in platinum-sensitive ovarian cancer patients, including those with prior PARP inhibitor exposure.
WCG's Activation Intelligence targets clinical trial rework by catching document conflicts before activation, saving sites ...
A Nature Neuroscience study separates psilocybin's neuroplastic effects from its hallucinogenic ones, and it should reshape ...
MA beneficiaries received kidney transplants at nearly half the rate of traditional Medicare patients post-Cures Act, a ...
OD-001 Phase 2a ulcerative colitis study hits primary endpoint with 2.4-point modified Mayo score reduction at Week 12, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results